Is serum PSA a predictor of male hypogonadism?

Glina, Sidney

doi:10.20945/2359-3997000000356

Cited by 3 publications

(3 citation statements)

References 9 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…It has become a public health problem that has been paid close attention to at home and abroad. The diagnosis and treatment of elderly patients with chronic heart failure complicated with type 2 diabetes mellitus is also the focus of clinical research [ 38 ].…”

Section: Discussionmentioning

confidence: 99%

Effect of Chronic Heart Failure Complicated with Type 2 Diabetes Mellitus on Cognitive Function in the Elderly

Liu

Meng

Dong

2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

Objective. To explore the effect of chronic heart failure complicated with type 2 diabetes mellitus on cognitive function in the elderly. Methods. 600 patients with chronic heart failure were selected from January 2018 to January 2021. All patients were divided into observation group (A) and control group (B). A was chronic heart failure complicated with type 2 diabetes mellitus group. B was chronic heart failure group. The clinical effects of the two groups were observed. Results. Compared with the clinical indexes during and after operation, there were differences in operation time, postoperative recovery time, and treatment cost between A and B, but the difference is not significant (all P > 0.05 ). LVEF cardiac function index score, LVEF score of A compared with B, the difference was statistically significant ( P < 0.05 ). The MMSE score and MoCA score of the two groups were compared. Before operation, the MMSE score and MoCA score of A were lower than those of B, and the difference was statistically significant ( P < 0.05 ). After operation, the MMSE score and MoCA score in B were significantly higher than those in B, but the increasing trend of MMSE score and MoCA score in B was significantly higher than that in A ( P < 0.05 ). Comparison of HAMA score and HAMD score: before operation, the HAMA score and HAMD score were higher in A, but the difference is not significant ( P > 0.05 ). After operation, the scores of HAMA and HAMD in A and B decreased significantly, but the difference is not significant ( P > 0.05 ). Multivariate analysis showed that the fasting blood glucose and glycosylated hemoglobin were the risk factors of cognitive impairment. Conclusion. Type 2 diabetes mellitus in elderly patients with chronic heart failure will further aggravate cognitive impairment, and type 2 diabetes is an important independent risk factor affecting cognitive function, which accelerates cognitive impairment and significantly reduces the executive ability of elderly patients with chronic heart failure, resulting in a significant decline in patients’ ability to understand and apply information.

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of Chronic Heart Failure Complicated with Type 2 Diabetes Mellitus on Cognitive Function in the Elderly

Liu

Meng

Dong

2022

Evidence-Based Complementary and Alternative Medicine

View full text Add to dashboard Cite

show abstract

“…Henceforth, it becomes crucial to meticulously observe the levels of prostate-specific antigen (PSA) in debilitated males who are undergoing testosterone therapy for the condition of hypogonadism [22]. In contrast to initial expectations, it has been determined that prostate-specific antigen (PSA) lacks the necessary level of reliability as a clinical indicator for male hypogonadism [23].The significance of recognising the utilisation of testosterone as a therapeutic measure for hypogonadism in individuals with frailty lies in the lack of substantial evidence indicating its effect on prostate-specific antigen (PSA) levels. Moreover, it has been observed that the beneficial outcomes associated with testosterone intervention, such as enhancements in muscular strength, lean body mass, and overall well-being among debilitated males, exhibit a transient nature and cease to exist beyond a duration of six months subsequent to the termination of testosterone treatment [21,24].…”

Section: Psa Levels and Health Status Of Frail Patientsmentioning

confidence: 99%

Prostate- Specific Antigen (PSA) Significance in Frail and Sarcopenic Men

Kostakopoulos,

Bellos,

Katsimperis

et al. 2024

Preprint

View full text Add to dashboard Cite

According to the guidelines of the European Association of Urology (EAU), it is recommended to exclude PSA testing when the expected remaining lifespan is less than 10 years. In this study, we provide a comprehensive analysis of the impact of prostate-specific antigen (PSA) testing on the quality of life of elderly men who are frail. We conducted a comprehensive literature review to identify publications that examine the use of PSA as a screening and prognostic tool for prostatic illnesses in frail men. Our search included the following keywords: Prostate-specific antigen, Frailty, Prostate cancer screening, Hypogonadism, and Benign Prostatic Obstruction (BPO). Prostate-specific antigen (PSA) testing can be used to identify prostate cancer in its early and treatable stages in fragile men with a life expectancy of over 15 years. Additionally, PSA testing allows for the evaluation of the effectiveness of various prostate cancer treatments and the monitoring of testosterone replacement therapy for hypogonadism. PSA is also indicative of the clinical development of patients with benign prostatic obstruction (BPO). Nevertheless, PSA is being extensively provided without individualised patient assessment, contributing to the economic strain on healthcare systems. Conducting a frailty evaluation on men to determine the potential advantages of PSA tests on their quality of life will help minimise avoidable expenses.

show abstract

“…Hence frail men who receive Testosterone treatment for hypogonadism should have their PSA closely monitored [11]. On the contrary, PSA cannot be used as a reliable clinical marker for male hypogonadism [12].It is important to mention that testosterone treatment for hypogonadism in the frail, has not been shown to significantly change the PSA levels and the benefits of the treatment such as on muscle strength, lean mass and quality of life in frail men, are not maintained 6 months after cessation of testosterone [10,13].…”

Section: Psa Levels and Health Status Of Frail Patientsmentioning

confidence: 99%

Prostate- Specific Antigen (PSA) Significance in Frail Men

Kostakopoulos,

Bellos,

Katsimperis

et al. 2023

Preprint

View full text Add to dashboard Cite

Objectives With this study we present, for the first time to the best of our knowledge, the implications of PSA tests on the lives of frail men. Methods We searched the available literature for studies analyzing the role of PSA as a screening and prognostic tool for prostatic diseases in frail men, using keywords: Prostate-specific antigen, Frailty, Prostate cancer screening, Hypogonadism and Benign Prostatic Obstruction (BPO). Results PSA in frail men with more than 15 years life expectancy can detect prostate cancer in curable stages, while it enables monitoring response to different prostate cancer treatments and follow-up of testosterone replacement for hypogonadism. PSA also predicts clinical progression of patients with BPO. However, PSA is widely being offered, without personalized patient evaluation, adding to the financial burden of healthcare systems. Conclusion A frailty assessment of men for the potential benefit of PSA tests on their quality of life can reduce unnecessary costs.

show abstract

Is serum PSA a predictor of male hypogonadism?

Cited by 3 publications

References 9 publications

Effect of Chronic Heart Failure Complicated with Type 2 Diabetes Mellitus on Cognitive Function in the Elderly

Effect of Chronic Heart Failure Complicated with Type 2 Diabetes Mellitus on Cognitive Function in the Elderly

Prostate- Specific Antigen (PSA) Significance in Frail and Sarcopenic Men

Prostate- Specific Antigen (PSA) Significance in Frail Men

Contact Info

Product

Resources

About